别名 C1orf12、EGL nine (C.elegans) homolog 1、Egl nine homolog 1 + [14] |
简介 Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific proline found in each of the oxygen-dependent degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of HIF1A. Also hydroxylates HIF2A. Has a preference for the CODD site for both HIF1A and HIF1B. Hydroxylated HIFs are then targeted for proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Under hypoxic conditions, the hydroxylation reaction is attenuated allowing HIFs to escape degradation resulting in their translocation to the nucleus, heterodimerization with HIF1B, and increased expression of hypoxy-inducible genes. EGLN1 is the most important isozyme under normoxia and, through regulating the stability of HIF1, involved in various hypoxia-influenced processes such as angiogenesis in retinal and cardiac functionality. Target proteins are preferentially recognized via a LXXLAP motif. |
作用机制 CD47抑制剂 [+1] |
在研机构 杭州尚健生物技术有限公司初创企业 [+1] |
原研机构 杭州尚健生物技术有限公司初创企业 |
非在研适应症- |
最高研发阶段临床2/3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 PHD2抑制剂 |
在研机构 |
原研机构 英矽智能(香港)有限公司初创企业 |
在研适应症 |
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 PHD2抑制剂 |
在研适应症 |
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2024-05-26 |
申办/合作机构 |
开始日期2023-11-08 |
申办/合作机构 英矽智能(香港)有限公司初创企业 |
开始日期2021-03-17 |
申办/合作机构 |